Computational Biology Market to Grow at 13.6 billion by 2026: COVID Impact & Post COVID Analysis, Business Opportunities, and Strategies

 

Computational biology is an interdisciplinary applied science that studies biological systems using mathematical, theoretical, and computer simulation models based on basic biology concepts. The rise in R&D for drug development, the need for predictive models, and use in population-based sequencing efforts such as the human genome project are all driving market expansion. Computational bio-modeling uses computer-aided biological models to generalize methods and properly depict simulations in virtual space to review difficulties in biological models. Computational genetics is a branch of computational biology that studies genomic homology and internal biological systems through genome sequencing.

One of The most notable examples is the Human Genome Project, which successfully sequenced the whole human genome. Computational biology is used in neurology to see and comprehend three-dimensional simulation models of the brain by mapping complicated interconnected pathways. Computer-aided visualization techniques are used in computational pharmacology to mimic advanced drug-drug interactions in the lab.

In 2018, the global computational biology market was valued at USD 2.9 billion, with a CAGR of 21.5 percent predicted over the forecast year. Growing drug discovery R&D, demand for predictive models, use in population-based sequencing efforts like the human genome project, and government financing are all driving the market forward. For example, in March 2019, Ambrx Inc., a clinical-stage biopharmaceutical business specializing in protein therapies struck a research and development agreement with BeiGene, Ltd., a commercial-stage pharmaceutical company.

According to a new analysis, the global computational biology industry is estimated to reach USD 13.6 billion by 2026. During the forecast period, it is expected to grow at a CAGR of 21.3 percent.

Ambrx has developed a unique Expanded Genetic Code platform that allows non-natural amino acids to be incorporated into protein sequences in E. coli and Chinese Hamster Ovary (CHO) cells. Both companies will use Ambrx's drug discovery platforms in conjunction with the latter's knowledge expertise and resource pool to produce clinically advanced biologics medications.

North America is likely to play an important role in the worldwide market. During the projected period, strong government financing for genetic-based studies, an increase in public-private partnerships, and industry-academic cooperation are expected to favor regional growth. Due to government-funded population-based studies and foreign investments, Asia Pacific is expected to grow rapidly over the projection period. The New South Wales (NSW) provincial government, for example, funds aspirant researchers in genomic medicine research at the Garvan Institute of Medical Research each year.

Chemical Computing Group Inc., Compugen Ltd., Simulation Plus Inc., Genedata AG, Certara, Insilico Biotechnology AG, Accelrys, Rhenovia Pharma SAS, Entelos, Nimbus Discovery LLC and Rhenovia Pharma SAS are some of the leading companies. To expand their worldwide reach, most organizations focus on strategic alliances, agreements, and mergers and acquisitions.